Skip to Content

'
Najat C. Daw, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Postgraduate Training

7/1993-7/1996 Clinical Fellowship, Pediatric Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN
7/1992-6/1993 Clinical Residency, Pediatrics Level 3, Baylor College of Medicine, Houston, TX
7/1991-6/1992 Clinical Residency, Pediatrics Level 1/2, Baylor College of Medicine, Houston, TX
7/1990-6/1991 Clinical Residency, Pediatrics Level 3 - Chief Resident, American University of Beirut Medical Center, Beirut, Lebanon
7/1989-6/1990 Clinical Residency, Pediatrics Level 2, American University of Beirut Medical Center, Beirut, Lebanon
7/1988-6/1989 Clinical Internship, Pediatrics Level 1, American University of Beirut Medical Center, Beirut, Lebanon

Board Certifications

11/2012 Basic Life Support
2010 American Board of Pediatric Hematology-Oncology
2000 American Board of Pediatrics
1995 Pediatric Advanced Life Support
1993 Flex Examination (Parts I & II)
1992 Neonatal Resuscitation Program (NRP) Provider
1989 FMGEMS (Parts I & II)

Experience/Service

Academic Appointments

Associate Professor, Department of Pediatrics, University of Tennessee Health Science Center College of Medicine, Memphis, TN, 7/2005-7/2010
Associate Member, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, 4/2004-7/2010
Assistant Professor, Department of Pediatrics, University of Tennessee Health Science Center College of Medicine, Memphis, TN, 7/2000-6/2005
Associate Staff, Department of Pediatrics, Le Bonheur Children's Medical Center, Memphis, TN, 10/1997-6/2000
Assistant Member, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, 8/1996-3/2004

Honors and Awards

2005-2006 Honored member Strathmore's Who's Who
2001 Member of the National Registry of Who's Who
1994 Lester Fellowship Award
1984 Deans Honor List, American University of Beirut, Beirut, Lebanon

Selected Publications

Peer-Reviewed Original Research Articles

1. McCarville MB, Billups C, Wu J, Kaufman R, Kaste S, Coleman J, Sharp S, Nadel H, Charron M, Lederman H, Don S, Shochat S, Daw NC, Shulkin B. The role of PET-CT in assessing pulmonary nodules in children with solid malignancies. Am J Roentgenol. In Press.
2. Kaste SC, Brady SL, Yee B, McPherson VJ, Kaufman RA, Billups CA, Daw NC, Pappo AS. Is Routine Pelvic Surveillance Imaging Necessary in Patients with Wilms’ Tumor? Cancer 119(1):182-8, 2013. e-Pub 6/2012. PMID: 22736193.
3. Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD, Rao BN, Daw NC. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children’s Research Hospital experience. Cancer 119(14):2645-53, 2013. PMID: 23625626.
4. Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, Quintana J, Luchtman-Jones L, Villarroel M, and Santana VM. Frontline treatment of localized osteosarcoma without methotrexate: Results of the St. Jude Children's Research Hospital OS99 trial. Cancer 117(12):2770-8, 2011. PMID: 21656756.
5. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan JS, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A. Preliminary efficacy of the anti-insulin like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing Sarcoma. Journal of Clinical Oncology 29(34):4534-40, 2011. e-Pub 10/2011. PMID: 22025154.
6. Kaste SC, Waszilycsak GL, McCarville MB, Daw NC. Estimation of potential excell cancer incidence in pediatric thallium-201 imaging. AJR Am J Roentgenol 194(1):245-249, 1/2010. PMID: 20028929.
7. Hinds PS, Gattuso JS, Billups CA, West NK, Wu J, Rivera C, Quintana J, Villarroel M, Daw NC. Aggressive treatment of nonmetastatic osteosarcoma improves health-related quality of life in children and adolescents. Eur J Cancer 45(11):2007-2014, 2009. PMID: 19450974.
8. Wright KD, Green DM and Daw NC. Late effects of treatment for Wilms tumor. Pediatric Hematology/Oncology 26(6):407-413, 2009. PMID: 19657990.
9. Ness KK, Rao BN and Daw NC. More than physical function: HRQOL among children and adolescents with lower extremity bone sarcoma. Pediatric Blood and Cancer 53(3):310-311, 2009. PMID: 19544376.
10. Daw NC, Gregornik D, Rodman J, Marina N, Wu J, Kun LE, Jenkins JJ, McPherson V, Wilimas J, Jones DP. Renal function after ifosfamide, carboplatin, and etoposide (ICE) chemotherapy, nephrectomy, and radiotherapy in children with Wilms tumor. European Journal of Cancer 45(1):99-106, 2009. e-Pub 11/2008. PMID: 18996004.
11. Furman WL, Navid F, Daw NC, McCarville MB, McGregor Lm, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. Journal of Clinical Oncology 27(27):4599-4604, 2009. PMID: 19687340.
12. Inaba H, Khan RB, Laningham FH, Crews KR, Pui C-H, Daw NC. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 19(1):178-184, 2008.
13. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC. Combination of gemcitabine and docetaxel in treatment of children and young adults with refractory bone sarcoma. Cancer 113(2):419-425, 2008. e-Pub 5/2008.
14. Rivera GK, Quintana J. Villarroel M, Santana VM, Rodriguez-Galindo C, Neel MD, Velez G, Ribeiro RC, Daw NC. Transfer of complex frontline anticancer therapy to a developing country: The St. Jude osteosarcoma experience in Chile. Pediatric Blood and Cancer 50:1143-1146, 2008.
15. Weiss A, Khoury JD, Hoffer FA, Wu J, Billups CA, Heck RK, Quintant J, Poe D, Rao BN, and Daw NC. Telangiectatic osteosarcoma: The St. Jude Children's Research Hospital's experience. Cancer 109(8):1627-1637, 2007.
16. Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, and Santana VM. Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors. Journal of Clinical Oncology 24(4)(563-570), 2006.
17. Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD, and Meyer WH. Metastatic osteosarcoma: Results of two consecutive therapeutic trials at St. Jude Children's Research Hospital. Cancer 106:403-412, 2006.
18. Hartford CM, Wodowski KS, Rao BN, Khoury JD, Neel MD, and Daw NC. Osteosarcoma among children aged 5 years or younger: The St. Jude Children's Research Hospital experience. Journal of Pediatric Hematology/Oncology 28:43-47, 2006.
19. Kaste SC, Fuller CE, Saharia A, Rao BN, and Daw NC. Pediatric surface osteosarcoma: Clinical, pathologic, and radiologic features. Pediatric Blood and Cancer 47(2):152-162, 2006.
20. Saab R, Rao BN, Rodriguez-Galindo C, Billups CA, Fortenberry TN, and Daw NC. Osteosarcoma of the pelvis in children and young adults: The St. Jude Children's Research Hospital's experience. Cancer 103(7):1468-1474, 2005.
21. Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Croop JM, Reaman GH, and Adamson PC. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: A Children's Oncology Group Study. Journal of Clinical Oncology 23(25):6172-6180, 2005.
22. Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, Panetta JC, Gajjar AJ, and Stewart CF. A phase I and pharmacokinetic study of oral topotecan administered once daily for five days for two consecutive weeks to pediatric patients with refractory solid tumors. Journal of Clinical Oncology 22:829-837, 2004.
23. Crews KR, Stewart CF, Liu T, Rodriguez-Galindo C, Santana VM, and Daw NC. Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. Journal of Pediatric Hematology/Oncology 26(11):764-767, 2004.
24. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw NC, Jenkins III JJ, Gilbertson R, Germain GS, Harwood FC, and Houghton PJ. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Research 64(20):7491-7499, 2004.
25. Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP, and Daw NC. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 100:1724-1733, 2004.
26. Rodriguez-Galindo C, Shah N, McCarville MB, Billups CA, Neel MN, Rao BN, and Daw NC. Outcome after local recurrence of osteosarcoma: The St. Jude Children's Research Hospital experience (1970-2000). Cancer 100:1928-1935, 2004.
27. Cypriano MS, Jenkins JJ, Pappo AS, Rao BN, and Daw NC. Pediatric gastrointestinal stromal tumors and leiomyosarcoma: The St. Jude Children's Research Hospital experience and a review of the literature. Cancer 101:39-50, 2004.
28. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, and Dome JS. Telomerase expression predicts unfavorable outcome in osteosarcoma. Journal of Clinical Oncology 22(18):3790-3797, 2004.
29. Daw NC, Billups CA, Pappo AS, Jenkins JJ, Mahmoud HH, Krasin MJ, Rao BN. Malignant fibrous histiocytoma and other fibrohistiocytic tumors in pediatric patients. Cancer 97:2839-2847, 2003.
30. Rodriguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome J, Pappo AS, Rao BN, Pratt CB. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. Journal of Pediatric Hematology/Oncology 24:250-255, 2002.
31. Daw NC, Mahmoud HH, Meyer WH, Jenkins JJ. Kaste SC, Poquette CA, Kun LE, Pratt CB, Rao BN. Bone sarcomas of the head and neck in children: The St. Jude Children's Research Hospital experience. Cancer 88:2172-2180, 2000.

Abstracts

1. Shulkin BL, Davis JC, Navid F, Billups C, Santana V, Reddick Gene, Daw NC. FDG PET/CT in pediatric osteosarcoma: Comparison of standard & delayed scanning. SNMMI Annual Meeting, Vancouver, BC, Canada, 6/2013.
2. Al-Rahawan MM, Yang J, Wang C, Aldag JC, de Alarcon PA, West N, Hinds PS, Rubnitz JE, Daw NC. Anemia and health-related quality of life in pediatric patients undergoing treatment for acute myeloid leukemia or osteosarcoma. Presented at the 23rd annual meeting of the American Society of Pediatric Hematology/Oncology, Montreal, Canada, 4/2010.
3. Mirabello L, Pfeiffer R, Murphy G, Daw N, Patino-Garcia A, Trpisi R, Hoover RN, Douglass C, Schuz J, Craft AW, Savage SA. Height, birth-weight, and osteosarcoma risk in a large meta-analysis. Presented at the 101st AACR annual meeting, Washington, DC (abstract # 5748), 4/2010.
4. Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins J, Villarroel M, Luchtman-Jones L, Quintana J, Santana VM. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. Cancer 117(12):2770-8, 2011. Presented at the ASCO Annual Meeting, Orlando, Florida 27:528s (abstract #10036), 5/2009. PMID: 21656756.

Last updated: 8/26/2013